Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 Isozymes
- 6 October 2008
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 37 (1), 1-4
- https://doi.org/10.1124/dmd.108.023663
Abstract
The objectives of this study were to compare the drug-metabolizing activity of human CYP2D6.24 (I297L), CYP2D6.26 (I369T), and CYP2D6.27 (E410K) allelic isoforms with wild-type CYP2D6.1 and to express the CYP2D7 protein derived from an indel polymorphism (CYP2D7 138delT) and investigate its possible codeine O-demethylase activity. Successful creation of individual cDNAs corresponding to CYP2D6*24 (2853 A>C), CYP2D6*26 (3277 T>C), and CYP2D6*27 (3853 G>A) allelic variants and CYP2D7 was achieved via molecular cloning. The corresponding proteins, CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7, were expressed in insect cells by using a baculovirus-mediated expression system. All CYP2D proteins showed the empirical carbon monoxide difference spectra. We were surprised to find that the CYP2D7 protein was detected mainly in mitochondrial fractions, whereas all CYP2D6 allelic isoforms were present in the microsomal fraction. Furthermore, CYP2D7 did not produce any morphine from codeine. In contrast, CYP2D6.24, CYP2D6.26, and CYP2D6.27 allelic isoforms all showed active drug-metabolizing activities toward both codeine and dextromethorphan O-demethylation. Whereas CYP2D6.24 exhibited the highest intrinsic clearance in dextromethorphan O-demethylation (∼6-fold higher than that by CYP2D6.1), it had the lowest enzyme efficiency in codeine O-demethylation (∼50% lower than that by CYP2D6.1). Overall, the enzymatic consequences of CYP2D6 allelic isozymes are substrate dependent. These data would help preclinical and clinical assessments of the metabolic elimination of drugs that are mediated by human CYP2D enzyme.Keywords
This publication has 26 references indexed in Scilit:
- The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6Journal of Pharmacology and Experimental Therapeutics, 2008
- Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized MiceDrug Metabolism and Disposition, 2007
- The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of PhenotypeCancer Cell, 2007
- Frequency of the Frame-Shifting CYP2D7 138delT Polymorphism in a Large, Ethnically Diverse Sample PopulationDrug Metabolism and Disposition, 2007
- Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17Drug Metabolism and Disposition, 2007
- A Natural Variant of the Heme-Binding Signature (R441C) Resulting in Complete Loss of Function of CYP2D6Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6Pharmacogenetics and Genomics, 2006
- EXPRESSION, PURIFICATION, AND CHARACTERIZATION OF MOUSE CYP2D22Drug Metabolism and Disposition, 2006
- CYP2D6*36GENE ARRANGEMENTS WITHIN THECYP2D6LOCUS: ASSOCIATION OFCYP2D6*36WITH POOR METABOLIZER STATUSPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2006
- Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?Published by Rockefeller University Press ,2001